These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 23951413)

  • 1. LRP5 and bone mass regulation: Where are we now?
    Johnson ML
    Bonekey Rep; 2012; 1():1. PubMed ID: 23951413
    [TBL] [Abstract][Full Text] [Related]  

  • 2. N-cadherin interacts with axin and LRP5 to negatively regulate Wnt/beta-catenin signaling, osteoblast function, and bone formation.
    Haÿ E; Laplantine E; Geoffroy V; Frain M; Kohler T; Müller R; Marie PJ
    Mol Cell Biol; 2009 Feb; 29(4):953-64. PubMed ID: 19075000
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New explanation for autosomal dominant high bone mass: Mutation of low-density lipoprotein receptor-related protein 6.
    Whyte MP; McAlister WH; Zhang F; Bijanki VN; Nenninger A; Gottesman GS; Lin EL; Huskey M; Duan S; Dahir K; Mumm S
    Bone; 2019 Oct; 127():228-243. PubMed ID: 31085352
    [TBL] [Abstract][Full Text] [Related]  

  • 4. miR-375-3p negatively regulates osteogenesis by targeting and decreasing the expression levels of LRP5 and β-catenin.
    Sun T; Li CT; Xiong L; Ning Z; Leung F; Peng S; Lu WW
    PLoS One; 2017; 12(2):e0171281. PubMed ID: 28158288
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New Insights into Wnt-Lrp5/6-β-Catenin Signaling in Mechanotransduction.
    Kang KS; Robling AG
    Front Endocrinol (Lausanne); 2014; 5():246. PubMed ID: 25653639
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Where Wnts went: the exploding field of Lrp5 and Lrp6 signaling in bone.
    Williams BO; Insogna KL
    J Bone Miner Res; 2009 Feb; 24(2):171-8. PubMed ID: 19072724
    [TBL] [Abstract][Full Text] [Related]  

  • 7. LRP6 High Bone Mass Characterized in Two Generations Harboring a Unique Mutation of Low-Density Lipoprotein Receptor-Related Protein 6.
    Whyte MP; Mumm S; Baker JC; Zhang F; Sedighi H; Duan S; Cundy T
    JBMR Plus; 2023 Apr; 7(4):e10717. PubMed ID: 37065631
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reversing LRP5-dependent osteoporosis and SOST deficiency-induced sclerosing bone disorders by altering WNT signaling activity.
    Chang MK; Kramer I; Keller H; Gooi JH; Collett C; Jenkins D; Ettenberg SA; Cong F; Halleux C; Kneissel M
    J Bone Miner Res; 2014 Jan; 29(1):29-42. PubMed ID: 23901037
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Normal hematopoiesis and lack of β-catenin activation in osteoblasts of patients and mice harboring Lrp5 gain-of-function mutations.
    Galán-Díez M; Isa A; Ponzetti M; Nielsen MF; Kassem M; Kousteni S
    Biochim Biophys Acta; 2016 Mar; 1863(3):490-498. PubMed ID: 26681532
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lrp4, a novel receptor for Dickkopf 1 and sclerostin, is expressed by osteoblasts and regulates bone growth and turnover in vivo.
    Choi HY; Dieckmann M; Herz J; Niemeier A
    PLoS One; 2009 Nov; 4(11):e7930. PubMed ID: 19936252
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Peptide-based mediated disruption of N-cadherin-LRP5/6 interaction promotes Wnt signaling and bone formation.
    Haÿ E; Buczkowski T; Marty C; Da Nascimento S; Sonnet P; Marie PJ
    J Bone Miner Res; 2012 Sep; 27(9):1852-63. PubMed ID: 22576936
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lrp5 controls bone formation by inhibiting serotonin synthesis in the duodenum.
    Yadav VK; Ryu JH; Suda N; Tanaka KF; Gingrich JA; Schütz G; Glorieux FH; Chiang CY; Zajac JD; Insogna KL; Mann JJ; Hen R; Ducy P; Karsenty G
    Cell; 2008 Nov; 135(5):825-37. PubMed ID: 19041748
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lrp5 and Lrp6 play compensatory roles in mouse intestinal development.
    Zhong Z; Baker JJ; Zylstra-Diegel CR; Williams BO
    J Cell Biochem; 2012 Jan; 113(1):31-8. PubMed ID: 21866564
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mutations in LRP5 cause primary osteoporosis without features of OI by reducing Wnt signaling activity.
    Korvala J; Jüppner H; Mäkitie O; Sochett E; Schnabel D; Mora S; Bartels CF; Warman ML; Deraska D; Cole WG; Hartikka H; Ala-Kokko L; Männikkö M
    BMC Med Genet; 2012 Apr; 13():26. PubMed ID: 22487062
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BMP-2 controls alkaline phosphatase expression and osteoblast mineralization by a Wnt autocrine loop.
    Rawadi G; Vayssière B; Dunn F; Baron R; Roman-Roman S
    J Bone Miner Res; 2003 Oct; 18(10):1842-53. PubMed ID: 14584895
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lrp5 and Lrp6 exert overlapping functions in osteoblasts during postnatal bone acquisition.
    Riddle RC; Diegel CR; Leslie JM; Van Koevering KK; Faugere MC; Clemens TL; Williams BO
    PLoS One; 2013; 8(5):e63323. PubMed ID: 23675479
    [TBL] [Abstract][Full Text] [Related]  

  • 17. LRP5: From bedside to bench to bone.
    Williams BO
    Bone; 2017 Sep; 102():26-30. PubMed ID: 28341377
    [TBL] [Abstract][Full Text] [Related]  

  • 18. LRP5 mutations in osteoporosis-pseudoglioma syndrome and high-bone-mass disorders.
    Levasseur R; Lacombe D; de Vernejoul MC
    Joint Bone Spine; 2005 May; 72(3):207-14. PubMed ID: 15850991
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Wnt co-receptor LRP5 is essential for skeletal mechanotransduction but not for the anabolic bone response to parathyroid hormone treatment.
    Sawakami K; Robling AG; Ai M; Pitner ND; Liu D; Warden SJ; Li J; Maye P; Rowe DW; Duncan RL; Warman ML; Turner CH
    J Biol Chem; 2006 Aug; 281(33):23698-711. PubMed ID: 16790443
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pathogenic mutations and polymorphisms in the lipoprotein receptor-related protein 5 reveal a new biological pathway for the control of bone mass.
    Ferrari SL; Deutsch S; Antonarakis SE
    Curr Opin Lipidol; 2005 Apr; 16(2):207-14. PubMed ID: 15767861
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.